GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (STU:MAR) » Definitions » Quick Ratio

Maravai LifeSciences Holdings (STU:MAR) Quick Ratio : 10.47 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Maravai LifeSciences Holdings's quick ratio for the quarter that ended in Mar. 2024 was 10.47.

Maravai LifeSciences Holdings has a quick ratio of 10.47. It generally indicates good short-term financial strength.

The historical rank and industry rank for Maravai LifeSciences Holdings's Quick Ratio or its related term are showing as below:

STU:MAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.42   Med: 6.21   Max: 10.47
Current: 10.47

During the past 6 years, Maravai LifeSciences Holdings's highest Quick Ratio was 10.47. The lowest was 0.42. And the median was 6.21.

STU:MAR's Quick Ratio is ranked better than
80.83% of 1544 companies
in the Biotechnology industry
Industry Median: 3.59 vs STU:MAR: 10.47

Maravai LifeSciences Holdings Quick Ratio Historical Data

The historical data trend for Maravai LifeSciences Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Quick Ratio Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 1.57 2.28 7.34 7.31 7.41

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 8.70 8.33 7.41 10.47

Competitive Comparison of Maravai LifeSciences Holdings's Quick Ratio

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Quick Ratio falls into.



Maravai LifeSciences Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Maravai LifeSciences Holdings's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(641.819-47.131)/80.208
=7.41

Maravai LifeSciences Holdings's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(614.453-45.858)/54.3
=10.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maravai LifeSciences Holdings  (STU:MAR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Maravai LifeSciences Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (STU:MAR) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.